Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives $9.33 Consensus PT from Analysts

Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) has received a consensus recommendation of "Hold" from the ten brokerages that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and three have assigned a buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $9.33.

FULC has been the subject of a number of analyst reports. Royal Bank of Canada downgraded Fulcrum Therapeutics from an "outperform" rating to a "sector perform" rating and cut their target price for the stock from $15.00 to $4.00 in a research note on Thursday, September 12th. Bank of America lowered shares of Fulcrum Therapeutics from a "neutral" rating to an "underperform" rating and decreased their target price for the stock from $10.00 to $2.00 in a research report on Thursday, September 12th. Cantor Fitzgerald downgraded shares of Fulcrum Therapeutics from an "overweight" rating to a "neutral" rating in a report on Thursday, September 12th. Leerink Partnrs downgraded shares of Fulcrum Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Thursday, September 12th. Finally, Leerink Partners reaffirmed a "market perform" rating and issued a $4.00 target price on shares of Fulcrum Therapeutics in a report on Thursday, September 12th.

Fulcrum Therapeutics Stock Up 0.8 %

FULC stock traded up $0.03 during trading on Tuesday, hitting $3.60. The company had a trading volume of 854,330 shares, compared to its average volume of 1,038,018. The firm has a 50-day moving average price of $7.46 and a 200-day moving average price of $7.66. The firm has a market cap of $223.75 million, a PE ratio of -2.23 and a beta of 2.23. Fulcrum Therapeutics has a 1-year low of $2.87 and a 1-year high of $13.70.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last issued its quarterly earnings results on Wednesday, July 31st. The company reported $0.87 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.06) by $0.93. The business had revenue of $80.00 million for the quarter, compared to analyst estimates of $80.00 million. Fulcrum Therapeutics had a negative net margin of 3,470.05% and a negative return on equity of 8.28%. During the same period in the previous year, the business posted ($0.38) earnings per share. Sell-side analysts anticipate that Fulcrum Therapeutics will post -0.28 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of FULC. National Bank of Canada FI lifted its holdings in Fulcrum Therapeutics by 869.6% in the 2nd quarter. National Bank of Canada FI now owns 4,460 shares of the company's stock valued at $28,000 after purchasing an additional 4,000 shares in the last quarter. Capstone Investment Advisors LLC acquired a new position in shares of Fulcrum Therapeutics in the fourth quarter valued at approximately $68,000. Profund Advisors LLC purchased a new position in shares of Fulcrum Therapeutics during the second quarter valued at approximately $68,000. China Universal Asset Management Co. Ltd. boosted its position in Fulcrum Therapeutics by 66.7% during the first quarter. China Universal Asset Management Co. Ltd. now owns 11,916 shares of the company's stock worth $112,000 after acquiring an additional 4,766 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new stake in Fulcrum Therapeutics in the 1st quarter worth approximately $115,000. 89.83% of the stock is currently owned by institutional investors and hedge funds.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.